Pamela L Walker

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma
    Pamela L Walker
    Clin J Oncol Nurs 8:169-74. 2004
  2. ncbi Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma
    Kristel Polder
    Memorial Hermann Hospital, University of Texas Health Science Center at Houston, TX, USA
    Leuk Lymphoma 46:1807-11. 2005
  3. ncbi Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Nam H Dang
    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Br J Haematol 138:502-5. 2007
  4. ncbi Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
    Nam H Dang
    MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 10:1513-8. 2003
  5. ncbi Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
    Nam H Dang
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    J Clin Oncol 22:4095-102. 2004
  6. ncbi Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
    Nam H Dang
    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Br J Haematol 136:439-47. 2007
  7. ncbi Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience
    Maricer P Escalon
    Department of Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2091-8. 2005

Collaborators

Detail Information

Publications7

  1. ncbi Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma
    Pamela L Walker
    Clin J Oncol Nurs 8:169-74. 2004
    ..Oncology nurses must gain a better understanding of the unique mechanism of action of this agent and its side effects to successfully manage patients being treated with this novel therapy...
  2. ncbi Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma
    Kristel Polder
    Memorial Hermann Hospital, University of Texas Health Science Center at Houston, TX, USA
    Leuk Lymphoma 46:1807-11. 2005
    ..The clinical features and pathology were compatible with toxic epidermal necrolysis. This is the first reported case of toxic epidermal necrolysis in the literature associated with denileukin diftitox...
  3. ncbi Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Nam H Dang
    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Br J Haematol 138:502-5. 2007
    ..The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon...
  4. ncbi Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
    Nam H Dang
    MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 10:1513-8. 2003
    ..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications...
  5. ncbi Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
    Nam H Dang
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    J Clin Oncol 22:4095-102. 2004
    ..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL...
  6. ncbi Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
    Nam H Dang
    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Br J Haematol 136:439-47. 2007
    ..Further studies of denileukin diftitox in combination with other agents are warranted in previously untreated and relapsed/refractory T-NHL...
  7. ncbi Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience
    Maricer P Escalon
    Department of Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2091-8. 2005
    ..Although intensive treatments have been developed, it is unknown whether they are more effective than CHOP chemotherapy (cyclophosphamide, doxorubicin, oncovorin, and prednisone)...